文献速递肝病

每日诺氟沙星对比每周环丙沙星预防自发性细菌性腹膜炎:一项随机对照试验

Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
PubMed 文献 · Am J Gastroenterol · 2018-06-27

本研究为在韩国七家三级医院开展的开放标签随机对照试验,纳入腹水蛋白≤1.5 g/dL或有自发性细菌性腹膜炎(SBP)病史的肝硬化腹水患者,随机接受每日诺氟沙星或每周环丙沙星治疗并随访12个月。结果显示两组SBP发生率分别为7.3%与5.3%(P=0.712),1年无移植生存率分别为72.7%与73.7%(P=0.970),每周环丙沙星预防SBP的疗效不劣于每日诺氟沙星。

要点

  • 每周环丙沙星与每日诺氟沙星预防SBP的疗效相当,SBP发生率7.3% vs 5.3%(P=0.712)。
  • 两组1年无移植生存率分别为72.7%与73.7%(P=0.970),无显著差异。
  • 感染性并发症、肝肾综合征、肝性脑病及静脉曲张出血发生率组间均无显著差异。

核心结论

  • 在肝硬化腹水患者中,每周一次环丙沙星预防SBP的疗效与每日诺氟沙星相当。

研究设计与样本

  • 由研究者发起的开放标签随机对照试验,在韩国七家三级医院开展。
  • 筛查肝硬化腹水患者,腹水蛋白≤1.5 g/dL或有SBP病史者纳入,腹水多形核细胞计数需<250/mm3。
  • 患者按1:1随机分配至每日诺氟沙星组或每周环丙沙星组,随访12个月。
  • 共124例符合入组标准并随机分组(62:62),诺氟沙星组7例、环丙沙星组5例失访。
  • 主要终点为SBP的预防。

主要发现

  • SBP在诺氟沙星组发生4例(4/55),环丙沙星组发生3例(3/57),发生率分别为7.3%与5.3%(P=0.712)。
  • 1年无移植生存率两组分别为72.7%与73.7%(P=0.970)。
  • 感染性并发症、肝肾综合征、肝性脑病及静脉曲张出血发生率组间均无显著差异(所有P=ns)。
  • 与生存相关的因素为反映基础肝功能的模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: For the prevention of spontaneous bacterial peritonitis (SBP) in cirrhotic patients with ascites, norfloxacin 400 mg per day is recommended as a standard regimen. This study aims to investigate whether ciprofloxacin once weekly administration is not inferior to norfloxacin once daily administration for the prevention of SBP. METHODS: This is an investigator-initiated open-label randomized controlled trial conducted at seven tertiary hospitals in South Korea. Liver cirrhosis patients with ascites were screened, and enrolled in this randomized controlled trial if ascitic protein ≤1.5 g/dL or the presence of history of SBP. Ascitic polymorphonucleated cell count needed to be <250/mm3. Patients were randomly assigned into norfloxacin daily or ciprofloxacin weekly group, and followed-up for 12 months. Primary endpoint was the prevention of SBP. RESULTS: One hundred twenty-four patients met enrollment criteria and were assigned into each group by 1:1 ratio (62:62). Seven patients in the norfloxacin group and five patients in the ciprofloxacin group were lost to follow-up. SBP developed in four patients (4/55) and in three patients (3/57) in each group, respectively (7.3% vs. 5.3%, P = 0.712). The transplant-free survival rates at 1 year were comparable between the groups (72.7% vs. 73.7%, P = 0.970). Incidence of infectious complication, hepatorenal syndrome, hepatic encephalopathy, and variceal bleeding rates were not significantly different (all P = ns). The factors related to survival were models representing underlying liver function. CONCLUSION: Once weekly ciprofloxacin was as effective as daily norfloxacin for the prevention of SBP in cirrhotic patients with ascites.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yim HJ, Suh SJ, Jung YK, et al. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial. Am J Gastroenterol. 2018. PMID: 29946179. doi:10.1038/s41395-018-0168-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。